Recent case-control studies and metaanalyses have attempted to quantify the risks associated with individual thrombophilic defects and adverse clinical events in pregnancy, including fetal loss, preeclampsia, placental abruption and intrauterine growth restriction. This review has examined the evidence.
Introduction
Hereditary and acquired thrombophilias predispose individuals to a hypercoagulable state, and in pregnancy appear to be associated with abnormal placentation and placental damage. Early in pregnancy this may manifest as spontaneous loss. In later pregnancy, thrombophilias have been associated with complications such as stillbirth, preeclampsia, placental abruption, and intrauterine growth restriction (IUGR). There is growing evidence that women with thrombophilia are at increased risk of pregnancy-related venous thromboembolism (VTE) and adverse pregnancy complications. Recent case-control studies and metaanalyses have attempted to quantify such risks. The aim of this review is to evaluate developments in this area published since May 2003.
Since 2003, three small studies have been published which have investigated the association between inherited thrombophilias and pregnancy-related VTE [1 . -3 . ]. Furthermore, a systematic review and metaanalysis by Robertson et al. (L. Robertson, O. Wu, P. Langhorne, et al., unpublished data) examined the risk of thrombophilia and all pregnancy outcomes, including VTE. All authors of recent publications reported that women with an inherited thrombophilic mutation are at increased risk of developing a VTE in pregnancy or the puerperium. The odds ratios for VTE with different thrombophilic mutations are presented in Table 1 . The risk of pregnancy-related VTE in women with acquired thrombophilia remains unclear due to lack of studies.
Multiple thrombophilic defects have also been associated with an increased risk of venous thrombosis [4] . A retrospective case-control study has recently confirmed the synergistic effect for the 20210A prothrombin and the factor V Leiden (FVL) polymorphisms. Samama et al. [1 . ] compared the risk of VTE in the absence of prophylaxis in a retrospective study of 47 women with combined FVL and prothrombin G20210A mutations and in 82 women with the prothrombin mutation alone.
The risk of pregnancy-related VTE was almost threefold in women with both mutations compared with prothrombin alone in the ante-and postpartum periods. Even women who had no history of VTE before pregnancy were also at increased risk (OR 2.2, 95% CI 1.0-4.8).
Pregnancy loss
Absolute risks for pregnancy loss with thrombophilic polymorphisms are hard to establish, as previous pregnancy history and timing of loss can influence the risk. Furthermore, in studies of pregnancy loss, authors use various definitions according to the timing of loss.
Early pregnancy loss
A recent case-control study reported that positive lupus anticoagulants, anticardiolipin antibodies, and high levels of homocysteine are associated with increased risk of pregnancy loss before 9 weeks' gestation [5 . ]. Heritable thrombophilias and their association with single pregnancy loss in the first trimester have been addressed by a metaanalysis [6 . . ]. Pooled data from 14 case-control studies of FVL carriers generated an odds ratio of 1.8 (95% CI 1.2-2.7).
Robertson et al. (unpublished data) classified early pregnancy loss as spontaneous loss in the first or second trimester of pregnancy. Results from this metaanalysis showed that homozygous FVL carriers and women with hyperhomocysteinemia were at increased risk of suffering an early pregnancy loss, with odds ratios of 6.25 obtained for each thrombophilia. Anticardiolipin antibodies and lupus anticoagulants were also associated with early pregnancy loss (OR 3.40, 95% CI 1. 33-8.68 and OR 2.97, 95% CI 1.03-8.56, respectively).
Late pregnancy loss
Data on the association of thrombophilic genes and late pregnancy loss published to date are conflicting. Three recent case-control studies have failed to find a significant association between thrombophilia and late pregnancy loss [7 . -9 . ]. In contrast, Dudding and Attia [6 . . ] reported that FVL carriers were almost three times more likely to suffer an isolated third trimester loss (OR 2.8, 95% CI 1.3-6.2). Robertson et al. (unpublished data) estimated similar results, with odds ratios of 2.1 (95% CI 1.1-3.86) and 2.66 (1.28-5.53) for heterozygous forms of the FVL and prothrombin G20210A mutation, respectively. These conflicting results could potentially be explained by differences in study sample size, methodology, inclusion of high-risk groups, definition of intrauterine fetal death, and number of thrombophilic polymorphisms investigated.
Recurrent pregnancy loss
Many studies have investigated the relationship between heritable thrombophilia and recurrent pregnancy loss, and the majority found an association [10-18]. The results from both individual studies and systematic reviews, presented in Table 2 , indicate that the risk of fetal loss associated with thrombophilia depends on the history and timing of previous fetal losses.
It is clear that there are a number of reports suggesting thrombophilia to be a predisposing factor for pregnancy loss, while other authors have found no association. This discrepancy may be based on differences in the selection criteria of patients and controls. Taking all aspects into account, the major limiting factors of all the studies are small study groups, the heterogeneity of the design and the outcome measured. The timing of the loss is also relevant -very early losses are likely to be very heterogeneous in their aetiology while later losses are more likely to have a vascular component. A further reason for investigations with completely controversial observations may be because of differences in the genetic background of the population studied.
Preeclampsia
Three systematic reviews and metaanalyses investigating the association between preeclampsia and thrombo- ]. While the odds ratio obtained from combining cohort studies (n = 3032 pooled women) did not show a significant association between FVL and preeclampsia (OR 1.1, 95% CI 0.4-2.9), the results from pooling case-control studies reported that cases were found to be three times more likely to develop severe preeclampsia (OR 2.93, 95% CI 1.98-4.33). These results are in conjunction with a large population-based study, published in conjunction with a metaanalysis in 2002 [22] . The authors found that, when analysis was restricted to severe preeclampsia, there was a significant association with FVL and with MTHFR C677T homozygotes with pooled odds ratio of 2.84 (95% CI 1.95-4.14) and 1.5 (95% CI 1.02-2.23), respectively. However, no association was found between severe preeclampsia and prothrombin G20210A.
The reasons underlying differences in results when comparing the association between thrombophilia and preeclampsia are unclear. They may reflect different diagnostic criteria, small sample size and ethnicity of the population studied. An example to illustrate this point is a case-control study by Prasmusinto et al. [23 . ]. They reported that German or Croatian carriers of the FVL mutation had an odds ratio of 7.8 (95% CI 0.8-73.2) to develop preeclampsia. The mutation was not prevalent in any of the Indonesian cases with preeclampsia or control women. Nonetheless, data from recent studies suggest that prothrombotic genotypes may not be causative factors for preeclampsia, but may be linked to the severity of disease expression once the condition arises.
Placental abruption
The association between maternal FVL and placental abruption has been investigated in two recent metaanalyses. 
2.7)
, but the results from their case-control study suggest an increased prevalence of first-degree heritage for VTE in women with placental abruption.
Intrauterine growth restriction
The results of two metaanalyses conducted recently have both reported that carriers of FVL are at increased risk of experiencing a pregnancy complicated by IUGR (Table 3) ]. However, almost half of the pregnant women in the study were diagnosed with the HELLP syndrome, therefore the results of this study are not relevant here.
Management of thrombophilia in pregnancy
Several guidelines and reviews have been published to guide clinicians in administering and monitoring anticoagulation throughout pregnancy [27 . . ,28,29,30 . . ]. The efficacy of various treatments in the prevention of adverse obstetric outcomes, however, has not yet been firmly established [31 . . ]. For women with a history of recurrent pregnancy loss and hereditary thrombophilia, no adequate trials have been performed that point toward a beneficial effect of a treatment regimen on the subsequent pregnancy outcome. To date, several studies have supported previous suggestions that low-molecularweight heparin improves outcome of subsequent pregnancies [32] [33] [34] [35] [36] 37 . . ]. However, these studies have serious limitations. Subsequent pregnancy outcome was compared with patients' previous history of pregnancy loss, which by definition was poor, as this was a selection criterion for inclusion. One study has recently been conducted in which the outcome of antithrombotic treatment in women with a clearly defined obstetric history was not compared with the patients' previous history of pregnancy loss [37 . . ]. Rather, authors prospectively compared low-molecular-weight heparin and aspirin. This study found that low-molecular-weight heparin was superior to low-dose aspirin alone both in all women and in each subgroup defined according to the underlying constitutional thrombophilia. Further large-scale randomized controlled trials are required, however, to firmly establish the effectiveness of treatment for the prevention of pregnancy loss associated with thrombophilia.
Screening for thrombophilia in pregnancy
Despite the absence of evidence in supporting routine screening for thrombophilia, it has been estimated that approximately 25 000 tests for activated protein C resistance/FVL are performed each year in the UK alone [38] . There is no current evidence to support indiscriminate screening for thrombophilia in pregnancy for the prevention of VTE from a clinical or an economic perspective. Despite the significant risks of VTE associated with some thrombophilias, the prevalences of individual thrombophilias, and hence the absolute risk of preventable adverse clinical complications, are low [39] . There have been suggestions that selective screening based on prior personal or family history of VTE may be of some value [29] . However, one study of FVL screening concluded that, when compared with no screening, universal and selective screening of FVL based on prior history of VTE would incur additional management costs of £13 281 and £7535, respectively; neither of the strategies was cost-effective [40] . These findings were supported by a more recent study on the cost-effectiveness of a complete thrombophilia screen in different patient groups (O. Wu, L. Robertson, S. Twaddle, et al., unpublished data).
Conclusion
Despite the growing evidence in the literature, there are still gaps in our knowledge of thrombophilia and pregnancy. There is a lack of data for accurate estimates of the size of the risks of VTE and adverse pregnancy outcomes associated with the less prevalent thrombophilias, such as deficiencies in antithrombin, protein C and S and multiple thrombophilic defects; however, this may be due, in part, to the difficulty in collecting such data. In addition, the relative clinical and cost-effectiveness of different anticoagulation therapies in the prevention of VTE and pregnancy loss needs to be assessed. More large-scale studies are required to address these issues and better inform clinicians, and help to determine optimal management and prevention strategies of thrombophilia and associated adverse clinical events in pregnancy.
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